A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Third Republic (1870–1940) === During the Third Republic (1870–1940): Notable civil progress for women, particularly regarding rights and access to education, and the recognition of their necessity as part of the workforce following the First World War. May 19, 1874: Law on the labor of children and underage girls employed in industry: work in mines is prohibited for children under 12 and for women; certain industries may employ children aged between 10 and 12, with a daily maximum of 6 hours; outside of this, in all factories, manufacturing plants, and construction sites, the minimum employable age for children is 12—unless the child has a primary education certificate—and the workday must not exceed six hours, with breaks; if the child has a primary education certificate or is at least 15 years old, they may work a maximum of 12 hours per day, with breaks; night work is prohibited for all children under 16 and for young women up to the age of 21 in factories and manufacturing plants. 1875
===== Colombia ===== In July 2023, Lula and Colombian president Gustavo Petro met in Leticia to discuss the details of an Amazon Cooperation Treaty Organization (ACTO) summit scheduled to take place a month later. Both presidents also discussed trade and defence between Colombia and Brazil. In April 2024, Lula visited Colombia and opened the 2024 Bogota International Book Fair alongside president Gustavo Petro. The two countries later signed six cooperation agreements regarding several topics including human trafficking. Lula and Petro also discussed the crisis in Venezuela.
=== Generic names === Buserelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while buserelin acetate is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name, buséréline is its DCFTooltip Dénomination Commune Française, and buserelina is its DCITTooltip Denominazione Comune Italiana. While under development by Hoechst AG, buserelin was also known as HOE-766.
Sources: en.wikipedia.org
Many homes have a large kitchen area devoted to preparation of meals and food, and may have a dining room, dining hall, or another designated area for eating. Most societies also have restaurants, food courts, and food vendors so that people may eat when away from home, when lacking time to prepare food, or as a social occasion. At their highest level of sophistication, these places become "theatrical spectacles of global cosmopolitanism and myth." At picnics, potlucks, and food festivals, eating is the primary purpose of a social gathering. At many social events, food and beverages are made available to attendees. People usually have two or three meals a day. Snacks of smaller amounts may be consumed between meals. Doctors in the UK recommend three meals a day (with between 400 and 600 kcal per meal), with four to six hours between. Having three well-balanced meals (described as: half of the plate with vegetables, 1/4 protein food as meat, [...] and 1/4 carbohydrates as pasta, rice) will then amount to some 1800–2000 kcal, which is the average requirement for a regular person. In jurisdictions under Sharia law, eating may be proscribed for Muslim adults during the daylight hours of Ramadan.
The plant was ordered to be planted with great religious care at what is now known as the villa surbana, where it grew into a grove. According to Jane Clark Reeder, when Julio-Claudians had military success they would take a laurel branch from the villa.
The waves were focused (by curving the antenna) and refracted (by a prism-shaped graphene bilayer because the conductivity in the two-atom-thick prism is larger than in the surrounding one-atom-thick layer.) The plasmonic metal-graphene nanoantenna was composed by inserting a few nanometers of oxide between a dipole gold nanorod and the monolayer graphene. The used oxide layer here can reduce the quantum tunneling effect between graphene and metal antenna. With tuning the chemical potential of the graphene layer through field effect transistor architecture, the in-phase and out-phase mode coupling between graphene plasmonics and metal plasmonics is realized. The tunable properties of the plasmonic metal-graphene nanoantenna can be switched on and off via modifying the electrostatic gate-voltage on graphene.
A nanodisc is a synthetic model membrane system which assists in the study of membrane proteins. Nanodiscs are discoidal proteins in which a lipid bilayer is surrounded by molecules that are amphipathic molecules including proteins, peptides, and synthetic polymers. It is composed of a lipid bilayer of phospholipids with the hydrophobic edge screened by two amphipathic proteins. These proteins are called membrane scaffolding proteins (MSP) and align in double belt formation. Nanodiscs are structurally very similar to discoidal high-density lipoproteins (HDL) and the MSPs are modified versions of apolipoprotein A1 (apoA1), the main constituent in HDL. Nanodiscs are useful in the study of membrane proteins because they can solubilise and stabilise membrane proteins and represent a more native environment than liposomes, detergent micelles, bicelles and amphipols. The art of making nanodiscs has progressed past using only the MSPs and lipids to make particles, leading to alternative strategies like peptide nanodiscs that use simpler proteins and synthetic nanodiscs that do not need any proteins for stabilization.
Sources: en.wikipedia.org
=== Interpretation === The prothrombin time is the time it takes plasma to clot after addition of tissue factor (obtained from animals such as rabbits, or recombinant tissue factor, or from brains of autopsy patients). This measures the quality of the extrinsic pathway (as well as the common pathway) of coagulation. The speed of the extrinsic pathway is greatly affected by levels of functional factor VII in the body. Factor VII has a short half-life and the carboxylation of its glutamate residues requires vitamin K. The prothrombin time can be prolonged as a result of deficiencies in vitamin K, warfarin therapy, malabsorption, or lack of intestinal colonization by bacteria (such as in newborns). In addition, poor factor VII synthesis (due to liver disease) or increased consumption (in disseminated intravascular coagulation) may prolong the PT. The INR is typically used to monitor patients being treated with anticoagulants of the vitamin K antagonist type, such as warfarin. However, prothrombin time and INR are insufficient for monitoring therapy with direct oral anticoagulants (DOACs). The normal range for a healthy person not using warfarin is 0.8–1.2, and for people on warfarin therapy an INR of 2.0–3.0 is usually targeted, although the target INR may be higher in particular situations, such as for those with a mechanical heart valve. If the INR is outside the target range, a high INR indicates a higher risk of bleeding, while a low INR suggests a higher risk of developing a clot.
Evidence for depression being causally associated with isotretinoin use includes 41 reports of positive challenge/dechallenge/rechallenge with isotretinoin, involving administering isotretinoin, withdrawing the drug, and then re-administering it. The majority of these cases had no psychiatric history. There is also a temporal relationship between the development of depression and initiation of isotretinoin treatment, with most cases developing after 1–2 months of treatment. Further, higher doses of isotretinoin increase the risk of developing depression, with 25% of people showing depression on a dose of 3 mg/kg/day as compared with 3–4% at normal doses. Studies have uncovered several biological processes which may credibly explain the affective changes induced by isotretinoin.
Functionalized nanoparticles able to form anionic oxidants bonding thereby allowing the detection of carcinogenic substances at very low concentrations. Polymer nanospheres have been developed to measure organic contaminates in very low concentrations "Peptide nanoelectrodes have been employed based on the concept of thermocouple. In a 'nano-distance separation gap, a peptide molecule is placed to form a molecular junction. When a specific metal ion is bound to the gap; the electrical current will result conductance in a unique value. Hence the metal ion will be easily detected." Composite electrodes, a mixture of nanotubes and copper, have been created to detect substances such as organophosphorus pesticides, carbohydrates and other woods pathogenic substances in low concentrations.
The Parliamentary Commission on Standards finds that Lord Waheed Alli committed four minor breaches in the register of members' interests. 24 October – Chancellor Rachel Reeves announces the UK government is to change its self-imposed debt rules in order to make an extra £50bn available for spending at the forthcoming budget. Lee Waters announces he will step down from the Senedd at the 2026 election. 26 October – Commonwealth leaders agree the "time has come" for a conversation about reparations for the slave trade, despite the UK's wish to keep the topic off the agenda at the Commonwealth Heads of Government Meeting. Buckingham Palace announces that Charles III is expected to return to a "normal" schedule in 2025 after his trip to the Commonwealth summit proved to be a "perfect tonic". A video emerges that appears to show Mike Amesbury, the MP for Runcorn and Helsby, shouting and swearing at a man who is lying on the ground during an apparent disturbance. Secretary of State for Wales Jo Stevens is accused by the Conservatives of bringing her office into disrepute after recording a political interview on its premises, something which they say breaches the civil service code. 28 October – The speaker of the House of Commons, Lindsay Hoyle, reprimands the chancellor, Rachel Reeves, in the Commons for giving information to journalists in the US about the upcoming Budget, in potential contravention of the ministerial code, which expects major government announcements to be made in the Commons before to the news media.
The first genuine decay of atoms of oganesson was observed in 2002 at the Joint Institute for Nuclear Research (JINR) in Dubna, Russia, by a joint team of Russian and American scientists. Headed by Yuri Oganessian, a Russian nuclear physicist of Armenian ethnicity, the team included American scientists from the Lawrence Livermore National Laboratory in California. As the decay energy of 294Og matched that of 212mPo, a common impurity produced in fusion reactions aimed at producing superheavy elements, the announcement of the discovery was delayed until after a 2005 confirmatory experiment aimed at producing more oganesson atoms. The 2005 experiment used a different beam energy (251 MeV instead of 245 MeV) and target thickness (0.34 mg/cm2 instead of 0.23 mg/cm2). On 9 October 2006, the researchers announced that they had indirectly detected a total of three (possibly four) nuclei of oganesson-294 (one or two in 2002 and two more in 2005) produced via collisions of californium-249 atoms and calcium-48 ions.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.